/AKLI
AKLI Stock - Akili, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$0.43+0.25%
+$0.00 (+0.25%) • Jul 1
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.79
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.51
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+650.4%upside
Target: $3.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AKLI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.43 – $0.44
TARGET (TP)$3.25
STOP LOSS$0.40
RISK/REWARD1:85.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.73
52W High$1.25
52W Low$0.19
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $1.68M | $323,000 | $538,000 | $3.94M | $19.99M |
| Gross Profit | $859,000 | $-118,000 | $183,000 | $3.52M | $18.64M |
| Gross Margin | 51.2% | -36.5% | 34.0% | 89.4% | 93.3% |
| Operating Income | $-64,485,000 | $-90,677,000 | $-60,719,000 | $-25,436,000 | $-21,498,000 |
| Net Income | $-59,493,000 | $-7,964,000 | $-61,830,000 | $-25,646,000 | $-20,634,000 |
| Net Margin | -3545.5% | -2465.6% | -11492.6% | -651.1% | -103.2% |
| EPS | $-0.76 | $-0.10 | $-0.79 | $-0.33 | $-0.27 |
Company Overview
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$4
Average Target
↑ 708.1% Upside
Now
$2
Low
$4
Average
$5
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2022 | BofA Securities | Initiation | Neutral | $2 |
| October 25th 2022 | Credit Suisse | Initiation | Outperform | $5 |
| September 6th 2022 | Cowen | Initiation | Outperform | - |
Earnings History & Surprises
AKLIBeat Rate
57%
Last 7 quarters
Avg Surprise
-7.9%
EPS vs Estimate
Beats / Misses
4/2
1 met exactly
Latest EPS
$-0.18
Q3 2024
EPS Surprise History
Q4 22
-35.0%
$-0.27vs$-0.20
Q1 23
-107.4%
$-0.56vs$-0.27
Q2 23
0.0%
$-0.18vs$-0.18
Q3 23
+20.0%
$-0.16vs$-0.20
Q4 23
+9.1%
$-0.20vs$-0.22
Q1 24
+36.4%
$-0.14vs$-0.22
Q2 24
+21.4%
$-0.11vs$-0.14
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 8, 2024 | — | $-0.18 | — | — |
Q2 2024 | May 14, 2024 | $-0.14 | $-0.11 | +21.4% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.22 | $-0.14 | +36.4% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.22 | $-0.20 | +9.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.18 | $-0.18 | 0.0% | = MET |
Q1 2023 | Mar 7, 2023 | $-0.27 | $-0.56 | -107.4% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.20 | $-0.27 | -35.0% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | — | $-0.29 | — | — |
Q2 2022 | May 16, 2022 | — | $-0.28 | — | — |
Q1 2022 | Mar 23, 2022 | — | $-0.25 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.23 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.10 | — | — |
Latest News
Loading news...
Frequently Asked Questions about AKLI
What is AKLI's current stock price?
Akili, Inc. (AKLI) is currently trading at $0.43 per share. The stock has moved +0.25% today.
What is the analyst price target for AKLI?
The average analyst price target for AKLI is $3.25, based on 1 analyst.
What sector is Akili, Inc. in?
Akili, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is AKLI's market cap?
Akili, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does AKLI pay dividends?
No, Akili, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBLNF
Babylon Holdings Limited
$0.00
Mkt Cap: $0.0B
CRBKF
Carebook Technologies Inc.
$0.03
Mkt Cap: $0.0B
HBCNF
HealthBeacon plc
$0.50
Mkt Cap: $0.0B
MNNDF
Nurosene Health Inc.
$0.33
Mkt Cap: $0.0B
MSPR
MSP Recovery, Inc.
$0.20
Mkt Cap: $0.0B
RTNXF
Renalytix Plc
$0.08
Mkt Cap: $0.0B
SNCE
Science 37 Holdings, Inc.
$5.75
Mkt Cap: $0.0B
STRM
Streamline Health Solutions, Inc.
$5.33
Mkt Cap: $0.0B
THKKF
Think Research Corporation
$0.23
Mkt Cap: $0.0B
TREIF
Rocket Doctor Ai Inc.
$0.49
Mkt Cap: $0.0B
Explore stocks similar to AKLI for comparison